It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Increased Crabp2 levels have been found in various types of cancer, and are associated with poor patients’ survival. Although Crabp2 is found to be overexpressed in lung cancer, its role in metastasis of lung cancer is unclear. In this study, Crabp2 was overexpressed in high-metastatic C10F4 than low-metastatic lung cancer cells. Analysis of clinical samples revealed that high CRABP2 levels were correlated with lymph node metastases, poor overall survival, and increased recurrence. Knockdown of Crabp2 decreased migration, invasion, anoikis resistance, and in vivo metastasis. Crabp2 was co-immunoprecipitated with HuR, and overexpression of Crabp2 increased HuR levels, which promoted integrin β1/FAK/ERK signaling. Inhibition of HuR or integrin β1/FAK/ERK signaling reversed the promoting effect of Crabp2 in migration, invasion, and anoikis resistance. Knockdown of Crabp2 further inhibited the growth of cancer cells as compared with that by gemcitabine or irinotecan alone. The expression of Crabp2 in human lung tumors was correlated with stress marker CHOP. In conclusion, our findings have identified the promoting role of Crabp2 in anoikis resistance and metastasis. CRABP2 may serve as a prognostic marker and targeting CRABP2 may be exploited as a modality to reduce metastasis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 National Health Research Institutes, Institute of Molecular and Genomic Medicine, Miaoli County, Taiwan (GRID:grid.59784.37) (ISNI:0000000406229172); National Central University, Department of Life Sciences, Taoyuan, Taiwan (GRID:grid.37589.30) (ISNI:0000 0004 0532 3167)
2 National Health Research Institutes, Institute of Molecular and Genomic Medicine, Miaoli County, Taiwan (GRID:grid.59784.37) (ISNI:0000000406229172); National Taiwan University, Institute of Molecular and Cellular Biology, Taipei, Taiwan (GRID:grid.19188.39) (ISNI:0000 0004 0546 0241)
3 National Health Research Institutes, Institute of Molecular and Genomic Medicine, Miaoli County, Taiwan (GRID:grid.59784.37) (ISNI:0000000406229172); China Medical University, Graduate Institute of Integrated Medicine, Taichung, Taiwan (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092)
4 National Health Research Institutes, Institute of Molecular and Genomic Medicine, Miaoli County, Taiwan (GRID:grid.59784.37) (ISNI:0000000406229172)
5 National Health Research Institutes, Institute of Molecular and Genomic Medicine, Miaoli County, Taiwan (GRID:grid.59784.37) (ISNI:0000000406229172); National Central University, Department of Life Sciences, Taoyuan, Taiwan (GRID:grid.37589.30) (ISNI:0000 0004 0532 3167); National Taiwan University, Institute of Molecular and Cellular Biology, Taipei, Taiwan (GRID:grid.19188.39) (ISNI:0000 0004 0546 0241); China Medical University, Graduate Institute of Integrated Medicine, Taichung, Taiwan (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092); China Medical University, Chinese Medical Research Center, Taichung, Taiwan (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092)